NCT04327063View on ClinicalTrials.gov

MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

January 28, 2022

Conditions
Malignant Neoplasm of Breast
Interventions
DRUG

Saline

Injection of the solution of Saline not exceeding 30 mL of maximal volume.

DRUG

Ropivacaine

Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume

Trial Locations (4)

54500

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

63000

Centre Jean Perrin, Clermont-Ferrand

75005

Institut Curie, Paris

75020

Hopital Tenon, Paris

All Listed Sponsors
lead

Institut Curie

OTHER

NCT04327063 - MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery | Biotech Hunter | Biotech Hunter